J&J's financial results are considered a bellwether for the broader health sector. The company posted $21.38 billion in total sales for the first three months of 2024, up more than 2% from the same quarter in 2023. The pharmaceutical giant booked net income of $5.35 billion, or $2.20 per share during the quarter.Johnson & Johnson (J&J) has announced a robust financial performance for the fourth quarter (Q4) of 2023, with net earnings reaching $4.1bn – a substantial 28% increase from $3.2bn in the same quarter of the previous year. The company's reported sales growth stood at 7.3%, escalating to $21.4bn from $19.9bn in Q4 2022.According to Johnson & Johnson's latest financial reports the company's current revenue (TTM ) is $89.65 B. In 2022 the company made a revenue of $91.14 B a decrease over the years 2021 revenue that were of $93.77 B. The revenue is the total amount of income that a company generates by the sale of goods or services.
Who owns Johnson & Johnson : Johnson & Johnson is mainly owned by institutional investors, with over 70% of shares held. The 10 largest shareholder of Johnson & Johnson in December 2023 were: The Vanguard Group (9.52%) BlackRock (7.73%)
Is Johnson & Johnson overvalued
Intrinsic Value. The intrinsic value of one JNJ stock under the Base Case scenario is 161.03 USD. Compared to the current market price of 151.27 USD, Johnson & Johnson is Undervalued by 6%.
Is Johnson and Johnson a good company to invest in : In the last year, 23 stock analysts published opinions about JNJ-N. 15 analysts recommended to BUY the stock. 7 analysts recommended to SELL the stock. The latest stock analyst recommendation is .
The business is still showing decent growth
On April 16, J&J reported its latest results, which demonstrated continued growth. Revenue of $21.4 billion for the first three months of the year represented a modest 2% increase from the same period last year. Part of the reason we've been so successful the past 130-plus years is that we've been able to constantly adapt and identify new solutions for our patients and customers. But to stay relevant and vibrant for the next 130 years, we must continue to innovate across our businesses.
Is Johnson and Johnson successful
The company has 128,700 employees worldwide, and total annual revenue exceeding $70 billion. Johnson & Johnson is considered the grandfather of workplace health promotion.Top revenue-producing drugs include: Stelara, Darzalex, Imbruvica, Tremfya, Erleada, Uptravi, Invega, Symtuza, Opsumit. Medical Device Sales – $23 billion. Top revenue-producing devices include: Hip implants, knee implants, spine implants, contact lenses and surgery products such as surgical mesh.Over the years, the company pushed further into the health and wellness industry by developing, innovating, and marketing new and improved products aimed at consumers. Johnson & Johnson's array of consumer goods isn't merely wide, but dominant. Vanguard Group Inc
Largest shareholders include Vanguard Group Inc, BlackRock Inc., State Street Corp, VTSMX – Vanguard Total Stock Market Index Fund Investor Shares, VFINX – Vanguard 500 Index Fund Investor Shares, Geode Capital Management, Llc, Morgan Stanley, State Farm Mutual Automobile Insurance Co, Spdr S&p 500 Etf Trust, and …
Is JNJ a good long-term stock : Johnson & Johnson (JNJ)
Johnson & Johnson (NYSE:JNJ) is a prominent member of the Dividend Kings, having raised its dividends for 61 consecutive years. Due to its long history of dividend payments, JNJ is among Wall Street's favorite long-term stocks.
Why is JNJ tanking : Guidance narrowed
Johnson & Johnson narrowed its full-year guidance slightly; the lowered top end of the range likely also contributed to the stock's sell-off. The company is now forecasting total sales of $88 billion to $88.4 billion; previously, it was guiding for $87.8 billion to $88.6 billion.
Is JNJ a risky investment
Johnson & Johnson isn't the safe stock it used to be
Until there is a resolution to the talc-related issues, the stock is simply too big of a risk these days. The legal bills pose a threat to the company's dividend and its long-term growth objectives. Total debt on the balance sheet as of March 2024 : $33.63 B
According to Johnson & Johnson's latest financial reports the company's total debt is $33.63 B. A company's total debt is the sum of all current and non-current debts.The split allows J&J's executives to focus more on developing innovations and expanding the businesses of medical technologies and pharmaceuticals. “We need to be a top-tier medical tech company and a top-tier pharmaceutical company, first and foremost,” Chief Financial Officer Joseph Wolk said.
Is JNJ in trouble : The Justice Department opened a probe into the products in July 2019, investigating what the company knew about the risk of cancer. Amid thousands of lawsuits over allegations of talc-induced health problems, Johnson & Johnson filed for bankruptcy twice, in October 2021 and April 2023.
![Kladsko-5-malý-Karlův-Most[1]](https://www.einarstrayorchestra.com/wp-content/uploads/2024/06/Kladsko-5-maly-Karluv-Most1-1024x692-250x120.jpg)
![Stubai[1]](https://www.einarstrayorchestra.com/wp-content/uploads/2024/06/Stubai1-250x120.jpg)
Antwort Is Johnson and Johnson a profitable company? Weitere Antworten – How profitable is Johnson & Johnson
J&J's financial results are considered a bellwether for the broader health sector. The company posted $21.38 billion in total sales for the first three months of 2024, up more than 2% from the same quarter in 2023. The pharmaceutical giant booked net income of $5.35 billion, or $2.20 per share during the quarter.Johnson & Johnson (J&J) has announced a robust financial performance for the fourth quarter (Q4) of 2023, with net earnings reaching $4.1bn – a substantial 28% increase from $3.2bn in the same quarter of the previous year. The company's reported sales growth stood at 7.3%, escalating to $21.4bn from $19.9bn in Q4 2022.According to Johnson & Johnson's latest financial reports the company's current revenue (TTM ) is $89.65 B. In 2022 the company made a revenue of $91.14 B a decrease over the years 2021 revenue that were of $93.77 B. The revenue is the total amount of income that a company generates by the sale of goods or services.
Who owns Johnson & Johnson : Johnson & Johnson is mainly owned by institutional investors, with over 70% of shares held. The 10 largest shareholder of Johnson & Johnson in December 2023 were: The Vanguard Group (9.52%) BlackRock (7.73%)
Is Johnson & Johnson overvalued
Intrinsic Value. The intrinsic value of one JNJ stock under the Base Case scenario is 161.03 USD. Compared to the current market price of 151.27 USD, Johnson & Johnson is Undervalued by 6%.
Is Johnson and Johnson a good company to invest in : In the last year, 23 stock analysts published opinions about JNJ-N. 15 analysts recommended to BUY the stock. 7 analysts recommended to SELL the stock. The latest stock analyst recommendation is .
The business is still showing decent growth
On April 16, J&J reported its latest results, which demonstrated continued growth. Revenue of $21.4 billion for the first three months of the year represented a modest 2% increase from the same period last year.
Part of the reason we've been so successful the past 130-plus years is that we've been able to constantly adapt and identify new solutions for our patients and customers. But to stay relevant and vibrant for the next 130 years, we must continue to innovate across our businesses.
Is Johnson and Johnson successful
The company has 128,700 employees worldwide, and total annual revenue exceeding $70 billion. Johnson & Johnson is considered the grandfather of workplace health promotion.Top revenue-producing drugs include: Stelara, Darzalex, Imbruvica, Tremfya, Erleada, Uptravi, Invega, Symtuza, Opsumit. Medical Device Sales – $23 billion. Top revenue-producing devices include: Hip implants, knee implants, spine implants, contact lenses and surgery products such as surgical mesh.Over the years, the company pushed further into the health and wellness industry by developing, innovating, and marketing new and improved products aimed at consumers. Johnson & Johnson's array of consumer goods isn't merely wide, but dominant.
Vanguard Group Inc
Largest shareholders include Vanguard Group Inc, BlackRock Inc., State Street Corp, VTSMX – Vanguard Total Stock Market Index Fund Investor Shares, VFINX – Vanguard 500 Index Fund Investor Shares, Geode Capital Management, Llc, Morgan Stanley, State Farm Mutual Automobile Insurance Co, Spdr S&p 500 Etf Trust, and …
Is JNJ a good long-term stock : Johnson & Johnson (JNJ)
Johnson & Johnson (NYSE:JNJ) is a prominent member of the Dividend Kings, having raised its dividends for 61 consecutive years. Due to its long history of dividend payments, JNJ is among Wall Street's favorite long-term stocks.
Why is JNJ tanking : Guidance narrowed
Johnson & Johnson narrowed its full-year guidance slightly; the lowered top end of the range likely also contributed to the stock's sell-off. The company is now forecasting total sales of $88 billion to $88.4 billion; previously, it was guiding for $87.8 billion to $88.6 billion.
Is JNJ a risky investment
Johnson & Johnson isn't the safe stock it used to be
Until there is a resolution to the talc-related issues, the stock is simply too big of a risk these days. The legal bills pose a threat to the company's dividend and its long-term growth objectives.
Total debt on the balance sheet as of March 2024 : $33.63 B
According to Johnson & Johnson's latest financial reports the company's total debt is $33.63 B. A company's total debt is the sum of all current and non-current debts.The split allows J&J's executives to focus more on developing innovations and expanding the businesses of medical technologies and pharmaceuticals. “We need to be a top-tier medical tech company and a top-tier pharmaceutical company, first and foremost,” Chief Financial Officer Joseph Wolk said.
Is JNJ in trouble : The Justice Department opened a probe into the products in July 2019, investigating what the company knew about the risk of cancer. Amid thousands of lawsuits over allegations of talc-induced health problems, Johnson & Johnson filed for bankruptcy twice, in October 2021 and April 2023.